Joseph E Malone1, Mohamed I Elkasaby1, Alan J Lerner2,3. 1. Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. 2. Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. Alan.lerner@uhhospitals.org. 3. Case Western Reserve University School of Medicine, Cleveland, OH, USA. Alan.lerner@uhhospitals.org.
Abstract
PURPOSE OF REVIEW: To review the pathophysiology of hypertension in Alzheimer's disease and related dementias and explore the current landscape of clinical trials involving treatment of hypertension to improve cognition. RECENT FINDINGS: Hypertension is increasingly recognized as a contributor to cognitive impairment. Clinical trials that explore blood pressure reductions with cognitive outcomes have been promising. Various antihypertensives have been evaluated in clinical trials, with growing interest in those agents that impact the renin-angiotensin-aldosterone system due to its own association with cognitive impairment. No antihypertensive agent has been found to be superior to others in reducing cognitive impairment risk or conferring neuroprotective benefits. In this review, the pathophysiology of and clinical trial data involving hypertension and dementia will be explored. Hypertension is a significant risk factor for the development of neurodegenerative dementias, and clinical trials have been overall favorable in improving cognition by reductions in blood pressure using antihypertensive agents.
PURPOSE OF REVIEW: To review the pathophysiology of hypertension in Alzheimer's disease and related dementias and explore the current landscape of clinical trials involving treatment of hypertension to improve cognition. RECENT FINDINGS: Hypertension is increasingly recognized as a contributor to cognitive impairment. Clinical trials that explore blood pressure reductions with cognitive outcomes have been promising. Various antihypertensives have been evaluated in clinical trials, with growing interest in those agents that impact the renin-angiotensin-aldosterone system due to its own association with cognitive impairment. No antihypertensive agent has been found to be superior to others in reducing cognitive impairment risk or conferring neuroprotective benefits. In this review, the pathophysiology of and clinical trial data involving hypertension and dementia will be explored. Hypertension is a significant risk factor for the development of neurodegenerative dementias, and clinical trials have been overall favorable in improving cognition by reductions in blood pressure using antihypertensive agents.
Authors: Costantino Iadecola; Kristine Yaffe; José Biller; Lisa C Bratzke; Frank M Faraci; Philip B Gorelick; Martha Gulati; Hooman Kamel; David S Knopman; Lenore J Launer; Jane S Saczynski; Sudha Seshadri; Adina Zeki Al Hazzouri Journal: Hypertension Date: 2016-10-10 Impact factor: 10.190
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: J Am Coll Cardiol Date: 2017-11-13 Impact factor: 24.094
Authors: Keenan A Walker; A Richey Sharrett; Aozhou Wu; Andrea L C Schneider; Marilyn Albert; Pamela L Lutsey; Karen Bandeen-Roche; Josef Coresh; Alden L Gross; B Gwen Windham; David S Knopman; Melinda C Power; Andreea M Rawlings; Thomas H Mosley; Rebecca F Gottesman Journal: JAMA Date: 2019-08-13 Impact factor: 56.272
Authors: Naveed Malek; Michael A Lawton; Diane M A Swallow; Katherine A Grosset; Sarah L Marrinan; Nin Bajaj; Roger A Barker; David J Burn; John Hardy; Huw R Morris; Nigel M Williams; Nicholas Wood; Yoav Ben-Shlomo; Donald G Grosset Journal: Mov Disord Date: 2016-10 Impact factor: 10.338
Authors: Elizabeth B Kirkland; Marc Heincelman; Kinfe G Bishu; Samuel O Schumann; Andrew Schreiner; R Neal Axon; Patrick D Mauldin; William P Moran Journal: J Am Heart Assoc Date: 2018-05-30 Impact factor: 5.501